Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Genotoxicity of retroviral integration in hematopoietic cells.

Nienhuis AW, Dunbar CE, Sorrentino BP.

Mol Ther. 2006 Jun;13(6):1031-49. Epub 2006 Apr 19. Review.

2.
3.

[Development and application of gene therapy technologies].

Ozawa K.

Uirusu. 2004 Jun;54(1):49-57. Review. Japanese.

4.

Insertional mutagenesis and clonal dominance: biological and statistical considerations.

Fehse B, Roeder I.

Gene Ther. 2008 Jan;15(2):143-53. Epub 2007 Nov 1. Review.

PMID:
17972922
5.

Progress toward the genetic treatment of the beta-thalassemias.

Sadelain M, Lisowski L, Samakoglu S, Rivella S, May C, Riviere I.

Ann N Y Acad Sci. 2005;1054:78-91. Review.

PMID:
16339654
6.

Stem cell clonality and genotoxicity in hematopoietic cells: gene activation side effects should be avoidable.

von Kalle C, Fehse B, Layh-Schmitt G, Schmidt M, Kelly P, Baum C.

Semin Hematol. 2004 Oct;41(4):303-18. Review.

PMID:
15508116
7.

Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors.

Haviernik P, Bunting KD.

Curr Gene Ther. 2004 Sep;4(3):263-76. Review.

PMID:
15384940
9.

Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients.

Romano G, Marino IR, Pentimalli F, Adamo V, Giordano A.

Drug News Perspect. 2009 May;22(4):185-96. doi: 10.1358/dnp.2009.22.4.1367704. Review.

PMID:
19536363
10.

Retroviral vectors: new applications for an old tool.

Barquinero J, Eixarch H, PĂ©rez-Melgosa M.

Gene Ther. 2004 Oct;11 Suppl 1:S3-9. Review.

PMID:
15454951
11.

Retroviral gene therapy: safety issues and possible solutions.

Yi Y, Hahm SH, Lee KH.

Curr Gene Ther. 2005 Feb;5(1):25-35. Review.

PMID:
15638709
12.

Gene therapy for severe combined immunodeficiencies.

Gaspar HB, Thrasher AJ.

Expert Opin Biol Ther. 2005 Sep;5(9):1175-82. Review.

PMID:
16120048
13.

[Hematopoietic malignancies and gene therapy].

Ozawa K.

Gan To Kagaku Ryoho. 2003 Apr;30(4):478-82. Review. Japanese.

PMID:
12722677
14.

The evolution of gene therapy in X-linked severe combined immunodeficiency.

Rans TS, England R.

Ann Allergy Asthma Immunol. 2009 May;102(5):357-62; quiz 363-5, 402. doi: 10.1016/S1081-1206(10)60504-2. Review.

PMID:
19492655
15.

Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies.

Goyama S, Kurokawa M.

Cancer Sci. 2009 Jun;100(6):990-5. doi: 10.1111/j.1349-7006.2009.01152.x. Epub 2009 Mar 9. Review.

16.

Perspectives of gene therapy for primary immunodeficiencies.

Chinen J, Puck JM.

Curr Opin Allergy Clin Immunol. 2004 Dec;4(6):523-7. Review.

PMID:
15640693
17.

Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency.

McCormack MP, Rabbitts TH.

N Engl J Med. 2004 Feb 26;350(9):913-22. Review. No abstract available.

PMID:
14985489
18.

Safety and efficacy in retrovirally modified haematopoietic cell therapy.

Li Z, Modlich U, Baum C.

Best Pract Res Clin Haematol. 2004 Sep;17(3):493-503. Review.

PMID:
15498719
19.

Gene therapy using hematopoietic stem cells.

Kohn DB.

Curr Opin Mol Ther. 1999 Aug;1(4):437-42. Review.

PMID:
11713757
20.

Supplemental Content

Support Center